CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gloucester Pharmaceuticals, Inc., a privately held cancer therapeutics development company, announced today that two abstracts detailing updated results from clinical trials of the Company’s lead product candidate, romidepsin (formerly known as depsipeptide, FK228), for the treatment of T-cell lymphomas will be presented at the 2006 American Society of Hematology’s 48th Annual Meeting, to be held December 9-12 in Orlando, FL.
